|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nuhn P, De Bono JS, Fizazi K, Freedland
SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN,
Yegnasubramanian S and Antonarakis ES: Update on systemic prostate
cancer therapies: Management of metastatic castration-resistant
prostate cancer in the era of precision oncology. Eur Urol.
75:88–99. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Resnick MJ, Koyama T, Fan KH, Albertsen
PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL,
Stroup AM, et al: Long-term functional outcomes after treatment for
localized prostate cancer. N Engl J Med. 368:436–445. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scher HI, Lu D, Schreiber NA, Louw J, Graf
RP, Vargas HA, Johnson A, Jendrisak A, Bambury R, Danila D, et al:
Association of AR-V7 on circulating tumor cells as a
treatment-specific biomarker with outcomes and survival in
castration-resistant prostate cancer. JAMA Oncol. 2:1441–1449.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hofman P and Popper HH: Pathologists and
liquid biopsies: To be or not to be? Virchows Arch. 469:601–609.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alix-Panabieres C and Pantel K: Challenges
in circulating tumour cell research. Nat Rev Cancer. 14:623–631.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yap TA, Lorente D, Omlin A, Olmos D and de
Bono JS: Circulating tumor cells: A multifunctional biomarker. Clin
Cancer Res. 20:2553–2568. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Antonarakis ES, Lu C, Wang H, Luber B,
Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, et
al: AR-V7 and resistance to enzalutamide and abiraterone in
prostate cancer. N Engl J Med. 371:1028–1038. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Andree KC, van Dalum G and Terstappen LW:
Challenges in circulating tumor cell detection by the CellSearch
system. Mol Oncol. 10:395–407. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cristofanilli M, Budd GT, Ellis MJ,
Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ,
Terstappen LW and Hayes DF: Circulating tumor cells, disease
progression, and survival in metastatic breast cancer. N Engl J
Med. 351:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
de Bono JS, Scher HI, Montgomery RB,
Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ
and Raghavan D: Circulating tumor cells predict survival benefit
from treatment in metastatic castration-resistant prostate cancer.
Clin Cancer Res. 14:6302–6309. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Habli Z, AlChamaa W, Saab R, Kadara H and
Khraiche ML: Circulating tumor cell detection technologies and
clinical utility: Challenges and opportunities. Cancers (Basel).
12:19302020. View Article : Google Scholar
|
|
13
|
Ferreira MM, Ramani VC and Jeffrey SS:
Circulating tumor cell technologies. Mol Oncol. 10:374–394. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Theil G, Fischer K, Weber E, Medek R, Hoda
R, Lucke K and Fornara P: The use of a new CellCollector to isolate
circulating tumor cells from the blood of patients with different
stages of prostate cancer and clinical outcomes-a proof-of-concept
study. PLoS One. 11:e01583542016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gorges TM, Penkalla N, Schalk T, Joosse
SA, Riethdorf S, Tucholski J, Lücke K, Wikman H, Jackson S, Brychta
N, et al: Enumeration and molecular characterization of tumor cells
in lung cancer patients using a novel in vivo device for capturing
circulating tumor cells. Clin Cancer Res. 22:2197–2206. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saucedo-Zeni N, Mewes S, Niestroj R,
Gasiorowski L, Murawa D, Nowaczyk P, Tomasi T, Weber E, Dworacki G,
Morgenthaler NG, et al: A novel method for the in vivo
isolation of circulating tumor cells from peripheral blood of
cancer patients using a functionalized and structured medical wire.
Int J Oncol. 41:1241–1250. 2012.PubMed/NCBI
|
|
17
|
Mandair D, Vesely C, Ensell L, Lowe H,
Spanswick V, Hartley JA, Caplin ME and Meyer T: A comparison of
cellcollector with cellsearch in patients with neuroendocrine
tumours. Endocr Relat Cancer. 23:L29–L32. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
de Bono JS, Attard G, Adjei A, Pollak MN,
Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, et
al: Potential applications for circulating tumor cells expressing
the insulin-like growth factor-I receptor. Clin Cancer Res.
13:3611–3616. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cristofanilli M: Circulating tumor cells,
disease progression, and survival in metastatic breast cancer.
Semin Oncol. 33 (Suppl 9):S9–S14. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Allard WJ, Matera J, Miller MC, Repollet
M, Connelly MC, Rao C, Tibbe AG, Uhr JW and Terstappen LW: Tumor
cells circulate in the peripheral blood of all major carcinomas but
not in healthy subjects or patients with nonmalignant diseases.
Clin Cancer Res. 10:6897–6904. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goldkorn A, Ely B, Quinn DI, Tangen CM,
Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci
MA, et al: Circulating tumor cell counts are prognostic of overall
survival in SWOG S0421: A phase III trial of docetaxel with or
without atrasentan for metastatic castration-resistant prostate
cancer. J Clin Oncol. 32:1136–1142. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Armstrong AJ: Epithelial-mesenchymal
transition in cancer progression. Clin Adv Hematol Oncol.
9:941–943. 2011.PubMed/NCBI
|
|
23
|
Alix-Panabieres C and Pantel K:
Circulating tumor cells: Liquid biopsy of cancer. Clin Chem.
59:110–118. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lambert AW, Pattabiraman DR and Weinberg
RA: Emerging biological principles of metastasis. Cell.
168:670–691. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gleghorn JP, Pratt ED, Denning D, Liu H,
Bander NH, Tagawa ST, Nanus DM, Giannakakou PA and Kirby BJ:
Capture of circulating tumor cells from whole blood of prostate
cancer patients using geometrically enhanced differential
immunocapture (GEDI) and a prostate-specific antibody. Lab Chip.
10:27–29. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Danila DC, Anand A, Sung CC, Heller G,
Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M and
Scher HI: TMPRSS2-ERG status in circulating tumor cells as a
predictive biomarker of sensitivity in castration-resistant
prostate cancer patients treated with abiraterone acetate. Eur
Urol. 60:897–904. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lorente D, Olmos D, Mateo J, Bianchini D,
Seed G, Fleisher M, Danila DC, Flohr P, Crespo M, Figueiredo I, et
al: Decline in circulating tumor cell count and treatment outcome
in advanced prostate cancer. Eur Urol. 70:985–992. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Scher HI, Heller G, Molina A, Attard G,
Danila DC, Jia X, Peng W, Sandhu SK, Olmos D, Riisnaes R, et al:
Circulating tumor cell biomarker panel as an individual-level
surrogate for survival in metastatic castration-resistant prostate
cancer. J Clin Oncol. 33:1348–1355. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Meyer CP, Pantel K, Tennstedt P, Stroelin
P, Schlomm T, Heinzer H, Riethdorf S and Steuber T: Limited
prognostic value of preoperative circulating tumor cells for early
biochemical recurrence in patients with localized prostate cancer.
Urol Oncol. 34:235.e11–6. 2016. View Article : Google Scholar
|
|
30
|
Todenhofer T, Park ES, Duffy S, Deng X,
Jin C, Abdi H, Ma H and Black PC: Microfluidic enrichment of
circulating tumor cells in patients with clinically localized
prostate cancer. Urol Oncol. 34:483.e9–e16. 2016. View Article : Google Scholar
|
|
31
|
Castle J, Morris K, Pritchard S and Kirwan
CC: Challenges in enumeration of CTCs in breast cancer using
techniques independent of cytokeratin expression. PLoS One.
12:e01756472017. View Article : Google Scholar : PubMed/NCBI
|
